Loading...
Loading...
Synergy Pharmaceuticals
SGYP today announced the start of
a phase 2 clinical trial to evaluate the safety and efficacy of SP-333,
its second-generation GC-C agonist and once-daily oral treatment, in
adult patients with opioid-induced constipation (OIC).
The multi-center, randomized, double-blind clinical trial will compare a
4-week, dose-ranging regimen of SP-333 (1.0, 3.0 and 6.0mg) against
placebo in adult patients taking opioid analgesics for chronic,
non-cancer pain for at least three months. The study plans to enroll
approximately 260 patients with OIC who have less than 3 spontaneous
bowel movements (SBMs) per week and who experience constipation-related
symptoms. The primary endpoint of the study is mean change from baseline
in the number of SBMs
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in